NASDAQ:EYES - Second Sight Medical Products Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.79 0.00 (0.00 %) (As of 02/22/2019 04:00 PM ET)Previous Close$0.79Today's Range$0.78 - $0.8052-Week Range$0.63 - $2.25Volume269,300 shsAverage Volume309,411 shsMarket Capitalization$60.31 millionP/E Ratio-1.34Dividend YieldN/ABeta2.26 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. It focuses on developing new technologies to treat the population of sight-impaired individuals. The company is developing the Orion Visual Cortical Prosthesis, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, or forms of cancer and trauma. It also offers Argus II Retinal Prosthesis System, an FDA and CE Mark approved device for treating retinitis pigmentosa. The company was formerly known as Second Sight LLC. and changed its name to Second Sight Medical Products, Inc. Second Sight Medical Products, Inc. was founded in 1998 and is headquartered in Sylmar, California with an additional office in Lausanne, Switzerland. Receive EYES News and Ratings via Email Sign-up to receive the latest news and ratings for EYES and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EYES Previous Symbol CUSIPN/A CIK1266806 Webwww.secondsight.com Phone818-833-5000Debt Debt-to-Equity RatioN/A Current Ratio1.37 Quick Ratio0.89Price-To-Earnings Trailing P/E Ratio-1.34 Forward P/E Ratio-1.52 P/E GrowthN/A Sales & Book Value Annual Sales$7.96 million Price / Sales7.58 Cash FlowN/A Price / Cash FlowN/A Book Value$0.14 per share Price / Book5.64Profitability EPS (Most Recent Fiscal Year)($0.59) Net Income$-28,510,000.00 Net Margins-408.41% Return on Equity-638.26% Return on Assets-279.24%Miscellaneous Employees112 Outstanding Shares76,336,000Market Cap$60.31 million Next Earnings Date3/6/2019 (Estimated) OptionableOptionable Second Sight Medical Products (NASDAQ:EYES) Frequently Asked Questions What is Second Sight Medical Products' stock symbol? Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES." How were Second Sight Medical Products' earnings last quarter? Second Sight Medical Products Inc (NASDAQ:EYES) issued its quarterly earnings data on Tuesday, August, 7th. The medical device company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02. The medical device company earned $1.91 million during the quarter, compared to the consensus estimate of $2.21 million. Second Sight Medical Products had a negative return on equity of 638.26% and a negative net margin of 408.41%. View Second Sight Medical Products' Earnings History. When is Second Sight Medical Products' next earnings date? Second Sight Medical Products is scheduled to release their next quarterly earnings announcement on Wednesday, March 6th 2019. View Earnings Estimates for Second Sight Medical Products. What price target have analysts set for EYES? 1 brokerages have issued twelve-month price targets for Second Sight Medical Products' shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate Second Sight Medical Products' stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 532.9% from the stock's current price. View Analyst Price Targets for Second Sight Medical Products. What is the consensus analysts' recommendation for Second Sight Medical Products? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Second Sight Medical Products in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Second Sight Medical Products. Has Second Sight Medical Products been receiving favorable news coverage? Media headlines about EYES stock have been trending positive recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Second Sight Medical Products earned a daily sentiment score of 2.7 on InfoTrie's scale. They also assigned media stories about the medical device company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. Who are some of Second Sight Medical Products' key competitors? Some companies that are related to Second Sight Medical Products include Cutera (CUTR), Electrocore (ECOR), Zynex (ZYXI), Helius Medical Technologies (HSDT), Fonar (FONR), Stereotaxis (STXS), BioSig Technologies (BSGM), Edap Tms (EDAP), IRIDEX (IRIX), Soleno Therapeutics (SLNO), Viveve Medical (VIVE), Precision Optics (PEYE), Digirad (DRAD), ENDRA Life Sciences (NDRA) and Non-Invasive Monitoring Systems (NIMU). What other stocks do shareholders of Second Sight Medical Products own? Based on aggregate information from My MarketBeat watchlists, some companies that other Second Sight Medical Products investors own include Corbus Pharmaceuticals (CRBP), Zynerba Pharmaceuticals (ZYNE), Cara Therapeutics (CARA), Micron Technology (MU), Canopy Growth (CGC), NVIDIA (NVDA), Alibaba Group (BABA), TransEnterix (TRXC), Visa (V) and VBI Vaccines (VBIV). Who are Second Sight Medical Products' key executives? Second Sight Medical Products' management team includes the folowing people: Mr. Jonathan Will McGuire, CEO, Pres & Director (Age 56)Mr. Stephen D. Okland Jr., Chief Commercial Officer (Age 55)Gunnar Bjorg, FounderMr. John T. Blake, CFO & Corp. Sec. (Age 43)Mr. William Patrick Ryan, Chief Operating Officer (Age 58) When did Second Sight Medical Products IPO? (EYES) raised $32 million in an initial public offering on Wednesday, November 19th 2014. The company issued 3,500,000 shares at $9.00 per share. MDB Capital Group, LLC served as the underwriter for the IPO. How do I buy shares of Second Sight Medical Products? Shares of EYES can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Second Sight Medical Products' stock price today? One share of EYES stock can currently be purchased for approximately $0.79. How big of a company is Second Sight Medical Products? Second Sight Medical Products has a market capitalization of $60.31 million and generates $7.96 million in revenue each year. The medical device company earns $-28,510,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. Second Sight Medical Products employs 112 workers across the globe. What is Second Sight Medical Products' official website? The official website for Second Sight Medical Products is http://www.secondsight.com. How can I contact Second Sight Medical Products? Second Sight Medical Products' mailing address is 12744 SAN FERNANDO ROAD BLDG. 3, SYLMAR CA, 91342. The medical device company can be reached via phone at 818-833-5000 or via email at [email protected] MarketBeat Community Rating for Second Sight Medical Products (NASDAQ EYES)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 180 (Vote Outperform)Underperform Votes: 189 (Vote Underperform)Total Votes: 369MarketBeat's community ratings are surveys of what our community members think about Second Sight Medical Products and other stocks. Vote "Outperform" if you believe EYES will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYES will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/22/2019 by MarketBeat.com StaffFeatured Article: What is the Dow Jones Industrial Average (DJIA)?